RT Journal Article
T1 Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib.
A1 Koutsoukos, Konstantinos
A1 Bamias, Aristotelis
A1 Tzannis, Kimon
A1 Espinosa Montaño, Marta
A1 Bozionelou, Vasiliki
A1 Christodoulou, Christos
A1 Stefanou, Dimitra
A1 Kalofonos, Haralabos
A1 Duran, Ignacio
A1 Papazisis, Konstantinos
K1 everolimus
K1 pazopanib
K1 renal cell carcinoma
AB We aimed to provide real-life data on the outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus as second-line treatment after failure of first-line pazopanib. Data from the medical charts of mRCC patients from 8 centers in Greece and Spain were reviewed. All patients had received or were continuing to receive second-line everolimus treatment after failure of first-line treatment with pazopanib. No other previous therapies were allowed. The primary end point was the determination of progression-free survival (PFS). In total, 31 patients were enrolled. Of these, 26% had performance status (PS) >0, 88% were of intermediate/poor Memorial Sloan-Kettering Cancer Center (MSKCC) risk group, and only 61% had undergone prior nephrectomy. Median PFS was 3.48 months (95% CI: 2.37-5.06 months). Median overall survival (OS) from everolimus initiation was 8.9 months (95% CI: 6.47-13.14 months). Median OS from pazopanib initiation was 14.78 months (95% CI: 10.54-19.08 months). Furthermore, 32% of patients temporarily discontinued everolimus due to adverse events (AEs), and 22% of patients discontinued everolimus permanently due to toxicity. Most common toxicities were anemia (29%), stomatitis (26%), pneumonitis (19%), and fatigue (10%). Moreover, 14 AEs (27%) were graded as 3 or 4 and were reported by 13 patients (42%). This study provides data exclusively on the sequence pazopanib-everolimus in mRCC. Everolimus has a favorable safety profile and is active. The short PFS and OS could be attributed to the fact that the pazopanib-everolimus sequence was mainly offered to patients with adverse prognostic features, resulting in a modest increase in the combined OS of our population.
SN 1178-6930
YR 2017
FD 2017-10-06
LK http://hdl.handle.net/10668/11718
UL http://hdl.handle.net/10668/11718
LA en
DS RISalud
RD Apr 5, 2025